CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 0.1% - Time to Sell?

CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report)'s stock price fell 0.1% on Tuesday . The stock traded as low as $40.94 and last traded at $41.80. 447,191 shares changed hands during trading, a decline of 77% from the average session volume of 1,968,914 shares. The stock had previously closed at $41.85.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on CRSP. Barclays reduced their price target on CRISPR Therapeutics from $59.00 to $55.00 and set an "equal weight" rating on the stock in a report on Wednesday, November 6th. Royal Bank of Canada restated a "sector perform" rating and set a $53.00 price target on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. JMP Securities restated a "market outperform" rating and set a $86.00 price target on shares of CRISPR Therapeutics in a report on Friday, December 20th. Needham & Company LLC restated a "buy" rating and set a $84.00 price target on shares of CRISPR Therapeutics in a report on Tuesday, January 14th. Finally, StockNews.com upgraded CRISPR Therapeutics to a "sell" rating in a report on Monday, December 30th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $78.38.

CRISPR Therapeutics Stock Performance

The stock has a market capitalization of $3.57 billion, a P/E ratio of -14.77 and a beta of 1.68. The business has a fifty day simple moving average of $44.19 and a 200-day simple moving average of $47.57.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.42) by $0.41. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. The firm had revenue of $0.60 million for the quarter, compared to analysts' expectations of $6.65 million. During the same period in the prior year, the business earned ($1.41) EPS. On average, sell-side analysts anticipate that CRISPR Therapeutics AG will post -5.13 earnings per share for the current year.

Insider Transactions at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 15,000 shares of the company's stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $55.10, for a total transaction of $826,500.00. Following the transaction, the chief executive officer now directly owns 181,540 shares of the company's stock, valued at $10,002,854. This represents a 7.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 4.10% of the stock is owned by insiders.

Institutional Investors Weigh In On CRISPR Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Capital Market Strategies LLC purchased a new stake in CRISPR Therapeutics in the 4th quarter valued at $461,000. Capital Advisors Inc. OK raised its position in CRISPR Therapeutics by 8.1% in the 3rd quarter. Capital Advisors Inc. OK now owns 300,589 shares of the company's stock valued at $14,122,000 after buying an additional 22,583 shares during the last quarter. Geode Capital Management LLC raised its position in CRISPR Therapeutics by 3.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company's stock valued at $47,383,000 after buying an additional 35,196 shares during the last quarter. Granite Bay Wealth Management LLC purchased a new stake in CRISPR Therapeutics in the 2nd quarter valued at $2,375,000. Finally, State Street Corp raised its position in CRISPR Therapeutics by 25.0% in the 3rd quarter. State Street Corp now owns 2,992,988 shares of the company's stock valued at $140,611,000 after buying an additional 599,304 shares during the last quarter. 69.20% of the stock is owned by hedge funds and other institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.